Lee's Pharmaceutical (01513.HK): The Phase III clinical trial of Recombinant Humanized Monoclonal Antibody Injection against Human IL-17A/F has achieved its primary research endpoint.

Zhitong Finance News, Lee's Pharmaceutical (01513.HK) announced that recently, its controlling subsidiary, Zhuhai Lee's Monoclonal Antibody Biotechnology Co., Ltd. (Lee's Monoclonal Antibody), jointly developed "Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection" (LZM012 or the product) with Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., has achieved the primary endpoint of Phase III clinical trial.